Other research shows treatment leads to high patient satisfaction
Swallowing pills containing a concentrate of fecal bacteria successfully stops recurrent bouts of debilitating Clostridium difficile (C. diff) infection by rebalancing the bacteria in the gut, suggests a study being presented at the IDWeek 2013™ meeting today.
Infection from C. diff bacteria is such a concern that the Centers for Disease Control and Prevention (CDC) named it one of the three most urgent threats in its recent landmark report on antibiotic resistance. C. diff sickens half a million Americans and kills 14,000 every year. C. diff infection can occur after people take antibiotics, wiping out the good bacteria in the gastrointestinal (GI) system, allowing C. diff to flourish and leading to severe diarrhea. In some patients, infection continues to recur despite standard treatment with antibiotics. For patients trapped in that cycle, doctors have transplanted feces from healthy donors into their GI system to rebalance the bacteria and stop infections from recurring.
Fecal transplantation typically is delivered by enema, colonoscopy (placing a tube in the colon) or nose tube and is effective in nine out of 10 patients, according to published reports. The IDWeek research suggests the less-invasive pills are a viable and effective delivery method.
“Recurrent C. diff infection is such a miserable experience and patients are so distraught that many ask for fecal transplantation because they’ve heard of its success,” said Thomas Louie, MD, professor of medicine at the University of Calgary, Alberta, and lead author of the pill study. “Many people might find the idea of fecal transplantation off-putting, but those with recurrent infection are thankful to have a treatment that works.”
Indeed, additional research being presented at the meeting showed patients who received fecal transplantation through a tube in the nose were highly satisfied with the treatment, and said they would likely recommend it to a friend.
Fecal Transplantation by Pill
University of Calgary researchers reported a 100 percent success rate – none of the 27 patients who took the tablet-sized pills had a recurrence of C. diff, even though all of them previously had had at least four bouts of the infection. Patients ingested between 24 and 34 capsules containing fecal bacteria, often donated by family members.
To make the pills, researchers processed the feces until it contained only bacteria, and then encapsulated the bacterial concentrate inside three layers of gelatin capsule. This ensured the pills wouldn’t leak or disintegrate until they were past the stomach and into the small intestine – a potential advantage over other methods because it covers more of the GI tract, does not involve invasive and more costly procedures, and is more comfortable for patients, Dr. Louie said.
Dr. Louie said he first made pills for fecal transplantation when one patient failed to respond to the enema method on two occasions and also could not tolerate a nasal tube for medical reasons. The pills are made individually.
“The pills are a one-shot deal and seem to work. They are easier for patients and are well-tolerated,” said Dr. Louie. “It’s an exciting development in the field and could possibly even be used to maintain the balance of bacteria in the GI system in patients at risk for C. diff.””
Patient Satisfaction of Fecal Transplantation
In the study of fecal transplantation tolerance, researchers surveyed 28 patients three months after they had undergone the treatment through a tube fed through the nose and GI system to the small intestine. On a scale of one to 10, average patient scores were: 9.6 for overall satisfaction; 9.9 for ease; and 9.9 for likelihood of recommending the procedure to a family member or friend.
“Patients with C. diff often have 20 or more stools a day, which seriously affects quality of life and so they are very open to this treatment,” said Ravi Kamepalli, MD, an infectious diseases physician at the Regional Infectious Disease-Infusion Center, Lima, Ohio, and lead author of the study. “Human beings are 90 percent bacteria and once that balance is altered with antibiotics, opportunistic infections can cause serious problems. All we are doing with this treatment is resetting the balance.”
The Latest on: Clostridium difficile
- My Turn: Meghan Mimnaugh: Americans should know about deadly infectionon November 29, 2019 at 2:00 pm
Losing a loved one is always painful. It’s particularly excruciating when their death was preventable. Before my mom died from a clostridium difficile (or C diff) infection, I had never heard of it.
- Understanding The Hard Realities of Becoming A Full-Time Caregiveron November 29, 2019 at 7:55 am
Her husband was diagnosed in 2016 with Clostridium difficile, more commonly called C. difficile, an often debilitating infection in the colon that causes fever, diarrhea and abdominal pain. “After six ...
- What Are the Benefits of Probiotics?on November 27, 2019 at 2:00 am
Specific probiotics have also been shown to help treat pouchitis, ulcerative colitis, colic and infectious diarrhea, and to reduce the risk of developing Clostridium difficile infections after taking ...
- New discovery in C. difficile biology could lead to treatments for dangerous infectionson November 25, 2019 at 8:01 am
A process called sporulation that helps the dangerous bacterium Clostridium difficile (C. difficile) to survive inhospitable conditions and spread is regulated by epigenetics, factors that affect gene ...
- First Blastocystis Transmission to FMT Recipients Reportedon November 20, 2019 at 8:17 am
Dutch researchers have identified what they say is the first human transmission of Blastocystis subtypes (ST) 1 and 3 from donors to patients undergoing fecal microbial transplant (FMT) for recurrent ...
- Increase in use of penicillin during Nenagh Hospital superbug infection in 2018on November 14, 2019 at 9:08 am
When inspectors from the health watchdog, HIQA, visited last April, documentation showed that the hospital incidence of Clostridium difficile (C diff) infection in August 2018 was 20.4 cases per ...
- Clostridium Difficile Infection Treatment Market Factors Influencing the Industry Developmenton November 12, 2019 at 6:03 am
The market research report Clostridium Difficile Infection Treatment Market evaluates the historical, the latest values and current changes to predict the market for the coming years from 2019 to 2026 ...
- Meet Finn, Vancouver Coastal Health’s newest C. diff sniffer dogon November 7, 2019 at 10:19 am
Finn and his sister Traveller will be mentored by Angus and Dodger, who are the stars of the program. The canines are trained and certified to detect Clostridium difficile, which is also known as C.
- Clostridium Difficile Treatment Know which Players Undershooting Market Expectationson October 24, 2019 at 10:51 pm
Oct 25, 2019 (HTF Market Intelligence via COMTEX) -- Advance Market Analytics released a comprehensive study of 200+ pages on 'Clostridium Difficile Treatment' market with detailed insights on growth ...
- Clostridium Difficile Infection Treatment Marketon October 21, 2019 at 11:17 pm
The Clostridium Difficile Infection Treatment Market research provides complete estimation of CAGR of the concerned period in percentages which will guide the users to take choice-based decisions over ...
via Google News and Bing News